Compare Cytokinetics Inc (CYTK) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares Silver Trust — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while iShares Silver Trust trades at $59.83. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| CYTK | SLV | |
|---|---|---|
Market Cap | $10.78B | — |
Sector | Technology | — |
52-Week High | $87.26 | $105.57 |
52-Week Low | $34.31 | $33.89 |
Enterprise Value | $10.88B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
SLV (iShares Silver Trust) trades at $57.50, up 2.95% with a bullish technical signal supported by moving averages. The ETF provides direct exposure to physical silver, which has seen volatile trading after a 50% decline from early 2026 highs. Recent price action shows silver rebounding amid Fed policy uncertainty and strong industrial demand fundamentals.
Silver's outlook remains compelling due to constrained supply and growing industrial demand, though high volatility and Fed policy sensitivity pose risks. The current technical setup suggests potential for continued upside if silver maintains support above $56, with resistance near $59.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
